Opko Health, Inc.

Good day and welcome to the Opco Health second quarter 2026 Business Highlights and Financial Results conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. And to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ms. Vivian Cervantes of Investor Relations. Please go ahead, ma'am.

Vivian Cervantes Thank you, Operator. Good afternoon, everyone. This is Vivian Cervantes with Alliance Advisors IR. Thank you all for joining us on today's call to discuss Opco Health's financial results for the second quarter 2026. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking and as such are subject to risks and uncertainties that could materially affect the company's results. Those forward-looking statements include without limitation the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31st, 2025. Furthermore, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, July 27, 2026. Except as required by law, OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Regarding the format of today's call, Dr. Philip Frost, Chairman and Chief Executive Officer, will provide opening remarks. Dr. Elias Zerhouni, Vice Chairman and President, will then provide an overview of Opco's therapeutic segment, as well as bioreference health. After that, Adam Logal, Opco's CFO, will review the company's second quarter financial results and discuss Opco's financial outlook. And then we will open the call to questions. Now I'd like to turn the call over to Dr. Frost.

Good afternoon and thank you for joining us today. During the second quarter, we made meaningful progress in improving operating efficiency and profitability and in advancing our product pipeline. Modix continues to move forward with its present portfolio of five clinical trial programs in oncology, immunology, and vaccines, each with the potential to deliver first and best-in-class medicines. We initiated a Phase 1, 2A clinical safety and efficacy study in the U.S. of our GLP-1 glucagon candidate, and we plan to enroll 44 healthy volunteers and presumed MASH patients to assess single-dose tolerability and pharmacokinetics. OpcoBiologics is making progress with its human growth hormone antagonists to treat acromegaly, It's GLP-2 program for patients with short bowel syndrome, and it's oral PTH to treat hypoparathyroidism. And Genla, our growth hormone product, partnered with Pfizer, continues to increase market penetration as we advance label expansion clinical trials. I'm pleased that we ended the second quarter with a strong cash position, and a solid balance sheet that continues to fund our R&D portfolio at a meaningful level, while also returning capital to shareholders through our ongoing stock repurchase program. With that brief overview, I'll turn the call over to Elias. Elias?